Global Pharmaceutical Development and Access: Critical Issues of Ethics and Equity
Author:
- 1 July 2011
- journal article
- research article
- Vol. 13 (3) , 16-22
Abstract
The article presents global data on access to pharmaceuticals and discusses underlying barriers. Two are highly visible: pricing policies and intellectual property rights; two are less recognized: the regulatory environment and scientific and technological capacities. Two ongoing transitions influence and even distort the problem of universal access to medications: the epidemiologic transition to an increasing burden of chronic non-communicable diseases; and the growing role of biotechnology products (especially immunobiologicals) in the pharmacopeia. Examples from Cuba and Brazil are used to explore what can and should be done to address commercial, regulatory, and technological aspects of assuring universal access to medications.Keywords
This publication has 9 references indexed in Scilit:
- Control of Advanced Cancer: The Road to ChronicityInternational Journal of Environmental Research and Public Health, 2011
- Access to essential medicines in national constitutionsBulletin of the World Health Organization, 2010
- The Responsibility to Pay for Cancer Treatments: A Health Insurer's View of ValueThe Oncologist, 2010
- Basic Survival Needs and access to Medicines — Coming to Grips with TRIPS: Conversion + CalculationJournal of Law, Medicine & Ethics, 2010
- How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion QuestionJNCI: Journal of the National Cancer Institute, 2009
- Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysisThe Lancet, 2009
- Connecting immunology research to public health: Cuban biotechnologyNature Immunology, 2008
- The availability and affordability of selected essential medicines for chronicl diseases in six low- and middle-income countriesBulletin of the World Health Organization, 2007
- TRIPS, the Doha declaration and paragraph 6 decision: what are the remaining steps for protecting access to medicines?Globalization and Health, 2007